logo

Intellia Therapeutics, Inc. (NTLA)



Trade NTLA now with
  Date
  Headline
5/3/2019 8:39:25 AM Wedbush Raises Intellia Therapeutics, Inc. (NTLA) To Outperform From Neutral With $21 Up From $20 Price Target
12/6/2018 7:34:31 AM Intellia Therapeutics And Novartis Expand Cell Therapy Collaboration
11/2/2018 6:31:35 AM Wedbush Is Increasing Intellia Therapeutics, Inc. (NTLA) FY19 Estimate To -1.18 From -1.94
11/2/2018 6:31:13 AM Wedbush Is Raising Intellia Therapeutics, Inc. (NTLA) Q4 19 Estimate To -0.48 From -0.52
11/2/2018 6:30:56 AM Wedbush Is Raising Intellia Therapeutics, Inc. (NTLA) Q3 19 Estimate To -0.35 From -0.49
11/2/2018 6:30:36 AM Wedbush Is Raising Intellia Therapeutics, Inc. (NTLA) Q2 19 Estimate To -0.54 From -0.56
11/2/2018 6:30:17 AM Wedbush Is Cutting Intellia Therapeutics, Inc. (NTLA) Q1 19 Estimate To -0.50 From -0.38
11/2/2018 6:29:59 AM Wedbush Is Raising Intellia Therapeutics, Inc. (NTLA) FY18 Estimate To -1.89 From -2.00
11/2/2018 6:29:42 AM Wedbush Is Increasing Intellia Therapeutics, Inc. (NTLA) Q4 18 Estimate To -0.34 From -0.40
11/2/2018 6:23:22 AM Wedbush Cuts Intellia Therapeutics, Inc. (NTLA) To Neutral From Outperform With $20 Down from $36 Price Target
10/31/2018 7:41:05 AM Intellia Therapeutics Q3 Loss Per Share $0.53 Vs Loss $0.44 Prior Year
10/29/2018 4:41:16 PM Intellia Therapeutics Names Glenn Goddard EVP And CFO
10/18/2018 8:40:05 AM Intellia Therapeutics Presents New Data In In Vivo And Ex Vivo Programs At The 26th ESGCT
9/10/2018 7:02:53 AM F-star Appoints Nessan Bermingham As Chairman Of Board Of Directors
8/2/2018 10:08:57 AM Wedbush Is Increasing Intellia Therapeutics, Inc. (NTLA) FY18 Rev. Estimate To 38.6 M From 33.5 M
8/2/2018 10:08:35 AM Wedbush Is Increasing Intellia Therapeutics, Inc. (NTLA) FY18 Estimate To -2.00 From -2.12
8/2/2018 10:08:03 AM Wedbush Is Raising Intellia Therapeutics, Inc. (NTLA) Q3 18 Estimate To -0.57 From -0.62
8/1/2018 7:48:23 AM Intellia Therapeutics Q2 Net Loss $22.2 Mln Or $0.52/Shr Vs Loss $15.6 Mln Or $0.45/Shr Last Year
6/19/2018 9:10:02 AM CRISPR, Intellia Therapeutics And Caribou Biosciences Announce Grant Of US Patent For CRISPR/Cas9 Genome Editing
5/18/2018 7:25:49 AM Wedbush Reiterates Intellia Therapeutics, Inc. (NTLA) At Outperform With $36 Price Target